Webinar | Bringing the Power of CyTOF to COVID-19 Research

Mass cytometry in infectious disease

Bringing the Power of CyTOF to COVID-19 Research

Abstract:

The COVID-19 public health crisis affects everyone in our global community. Crucial questions about how SARS-CoV-2 affects our immune system and how to monitor the response to newly developed therapeutic interventions must be answered quickly to facilitate development of effective vaccines and improve therapeutic approaches.

In this recorded webinar, Andrew Quong, Chief Science Officer at Fluidigm, describes the important role that cytometry is playing in these efforts as well as how researchers are already using mass cytometry, Imaging Mass Cytometry™ and the Fluidigm genomics platforms in COVID-19 related research. In addition, he explains the Maxpar® Direct™ Immune Profiling System, a fast, reliable cytometric assay that includes an automated data analysis solution designed for use on CyTOF® systems.

Roberto Spada, Senior Market Development Manager, then shares results of a multi-site study with the Maxpar Direct Immune Profiling System to illustrate the inter-site and intra-site reproducibility of the assay. He also presents data showing that samples processed with the assay can be cryopreserved for up to four months without adverse impact on immune cell subset identification and enumeration.



About the presenters:

Andrew Quong, PhD
Chief Science Officer
Fluidigm

Roberto Spada, PhD
Senior Market Development Manager
Fluidigm



For Research Use Only. Not for use in diagnostic procedures.